Inhaled delivery of clofazimine - a high efficiency, flow independent, targeted, low cost DPI
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00039
- Awardee
-
Via Therapeutics, LLC UEI YHRZATLXKL46
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,599,145
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Pre-Solicitation · PHS20181 · Posted Jun 29, 2017
- Contract value 100% obligated
- $3,599,145.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Austin, TX 78750, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $2,999,221 | |
| Original award | $599,924 |
About this award
Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation seeking proposals to address topics within the National Institute of Allergy and Infectious Diseases' programs, including developing new therapeutics for tuberculosis. Work under this contract is to be completed in Austin, Texas by August 2023.
Quick answers
Who was awarded contract 75N93018C00039?
75N93018C00039 was awarded to Via Therapeutics, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 9, 2018.
How much is contract 75N93018C00039 worth?
The government has obligated $3,599,145 on 75N93018C00039.
Was contract 75N93018C00039 competed?
The extent of competition for 75N93018C00039 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award